Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract

Caterina Vicentini, Matteo Fassan, Edoardo D'Angelo, Vincenzo Corbo, Nicola Silvestris, Gerard J. Nuovo, Aldo Scarpa

Research output: Contribution to journalArticle

Abstract

It is well documented that dysregulation of microRNAs is a hallmark of human cancers. Thus, this family of small non-coding regulatory molecules represents an excellent source of sensitive biomarkers. Unique microRNAs expression profiles have been associated with different types and subsets of gastrointestinal tumors including gastroenteropancreatic neuroendocrine tumors (GEP-NETs). GEP-NETs are a heterogeneous group of epithelial neoplasms with neuroendocrine differentiation. At present, early detection and surgical resection of GEP-NETs represent the best chance for a cure. Thus, clinically useful biomarkers for GEP-NETs that strongly correlate with early detection are urgently needed. The purpose of this review is to summarize the role of miRNAs in GEP-NET carcinogenesis and their possible use as novel diagnostic, prognostic and predictive biomarkers.

Original languageEnglish
Pages (from-to)2458-2468
Number of pages11
JournalMolecules
Volume19
Issue number2
DOIs
Publication statusPublished - Feb 2014

    Fingerprint

Keywords

  • Gastrointestinal tract
  • In situ hybridization
  • MiRNAs
  • Neuroendocrine tumors
  • Pancreas

ASJC Scopus subject areas

  • Organic Chemistry
  • Medicine(all)

Cite this

Vicentini, C., Fassan, M., D'Angelo, E., Corbo, V., Silvestris, N., Nuovo, G. J., & Scarpa, A. (2014). Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract. Molecules, 19(2), 2458-2468. https://doi.org/10.3390/molecules19022458